Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Net Asset Quality Index
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Net Asset Quality Index of 55.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.30 Billion minus total liabilities of CN¥1.03 Billion yields net assets of CN¥1.27 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Beijing Sun Novo Pharmaceutical Research (688621) liquidity interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Beijing Sun Novo Pharmaceutical Research Co Ltd Net Asset Quality Index Over Time (2017–2025)
This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's Net Asset Quality Index has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the index stands at 55.1%, representing net assets of CN¥1.27 Billion against total assets of CN¥2.30 Billion CNY. Explore cash efficiency ratio of Beijing Sun Novo Pharmaceutical Research to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
The table below presents the year-by-year Net Asset Quality Index for Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Beijing Sun Novo Pharmaceutical Research market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 54.0% | CN¥1.23 Billion | CN¥2.28 Billion | CN¥1.05 Billion | ▼ -1.5 pp |
| 2024 | 55.5% | CN¥1.10 Billion | CN¥1.99 Billion | CN¥884.65 Million | ▼ -1.3 pp |
| 2023 | 56.7% | CN¥1.06 Billion | CN¥1.86 Billion | CN¥805.76 Million | ▼ -5.3 pp |
| 2022 | 62.1% | CN¥908.23 Million | CN¥1.46 Billion | CN¥554.86 Million | ▲ +0.1 pp |
| 2021 | 61.9% | CN¥769.64 Million | CN¥1.24 Billion | CN¥473.01 Million | ▲ +11.8 pp |
| 2020 | 50.1% | CN¥192.92 Million | CN¥384.86 Million | CN¥191.94 Million | ▲ +8.5 pp |
| 2019 | 41.6% | CN¥118.76 Million | CN¥285.51 Million | CN¥166.76 Million | ▲ +5.0 pp |
| 2018 | 36.6% | CN¥73.82 Million | CN¥201.50 Million | CN¥127.68 Million | ▲ +6.4 pp |
| 2017 | 30.2% | CN¥33.25 Million | CN¥110.07 Million | CN¥76.82 Million | — |